ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2009 Financial Results
To access the live call by phone, dial 913-981-4900. No passcode is required. The call also may be accessed through the Investor Information section of the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through November 3, 2008.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company's TAP technology uses antibodies to deliver one of ImmunoGen's proprietary cell-killing agents specifically to cancer targets. In addition to the Company's proprietary clinical pipeline, ImmunoGen collaborators Genentech, sanofi-aventis, Biogen Idec, and Biotest also are testing TAP compounds in the clinic, and a naked antibody is in clinical trials through the Company's collaboration with sanofi-aventis.
SOURCE: ImmunoGen, Inc.
Executive Director, Investor Relations and Corporate Communications
Carol Hausner, 781-895-0600